To partially address this question, we have tested whether tau monomer derived from PS19 mice (Fig. S4, A and B) or two different AD subjects (Fig. S4, C and D) retains its seeding activity after protein phosphatase PP2A treatment (32). The gene discussed is MAPT; the disease is Alzheimer disease.